Author

James Appel

Observed name: James E Appel

Observed institutions: Campbell University, PMG Research

OpenAlex ID: A5113326706

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

2019 · A. Blauvelt, A. Blauvelt, et al. · British Journal of Dermatology · 175

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

2022 · Ellen J. Kim, Aaron R. Mangold, et al. · JAMA Dermatology · 56

Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas

2020 · Luke Maxfield, Muneeb Shah, et al. · Journal of the American Academy of Dermatology · 31

717 - Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects

2024 · Jennifer L Parish, James E Appel, et al. · British Journal of Dermatology · 3

Low-Dose Isotretinoin: An Option for the Treatment of Scalp and Facial Rosacea.

2026 · Madeline Lillich, Mikel Muse, et al. · PubMed

Works count: 5

Citation count: 264

H-index: 3

I10-index: 3